Cardiothoracic Intensive Care Unit, Dupuytren II Hospital, University Teaching Hospital of Limoges, Limoges, France; René Labusquière Centre of Tropical Medicine, University of Bordeaux, Bordeaux, France; UMR 1094 Neuroépidémiologie Tropicale, University of Limoges, Limoges, France.
Intensive Care Unit, Félix Guyon Hospital, University Teaching Hospital of Saint Denis de La Réunion, Reunion Island, France.
J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1426-1430. doi: 10.1053/j.jvca.2019.12.043. Epub 2020 Jan 8.
The aim of the present study was to assess the post-pandemic mortality of influenza in patients receiving venovenous extracorporeal membrane oxygenation (VV-ECMO) in Reunion Island, France, by comparing the incidence with other patients undergoing VV-ECMO.
Retrospective, descriptive, and single-center cohort study. The primary outcome was the standardized mortality ratio for influenza based on the quartiles of the Respiratory Extracorporeal Membrane Oxygenation Survival Prediction score (RESP Score) in the reference population of patients undergoing VV-ECMO.
Intensive care unit (ICU), Felix Guyon Hospital, University Teaching Hospital of La Réunion, La Réunion, France.
Consecutive patients on ECMO with positive polymerase chain reaction for influenza.
None.
One hundred twenty-seven consecutive patients were hospitalized in the ICU with a positive influenza polymerase chain reaction from January 2013 to December 2017. Twenty-four influenza patients underwent ECMO including 18 patients with VV-ECMO. During this period, 72 patients requiring VV-ECMO were hospitalized in the ICU. The overall mortality rate of influenza patients on VV-ECMO was 61% versus 46% for non-influenza patients. The standardized mortality ratio per quartile of RESP Score was 1.28 (95% confidence interval 0.61-2.35).
In Reunion, the mortality of patients undergoing VV-ECMO for severe influenza is not lower than the expected mortality of all patients undergoing VV-ECMO.
本研究旨在评估法国留尼汪岛接受静脉-静脉体外膜肺氧合(VV-ECMO)治疗的流感患者的大流行后死亡率,方法是将流感患者的发病率与接受 VV-ECMO 治疗的其他患者进行比较。
回顾性、描述性和单中心队列研究。主要结局是根据接受 VV-ECMO 的患者参考人群的呼吸体外膜肺氧合生存预测评分(RESP 评分)四分位数计算的流感标准化死亡率。
重症监护病房(ICU),Felix Guyon 医院,法国留尼汪大学附属医院。
连续接受 ECMO 治疗且流感聚合酶链反应阳性的患者。
无。
2013 年 1 月至 2017 年 12 月,连续 127 例流感阳性聚合酶链反应患者在 ICU 住院。24 例流感患者接受 ECMO 治疗,其中 18 例为 VV-ECMO。在此期间,72 例需要 VV-ECMO 的患者在 ICU 住院。接受 VV-ECMO 的流感患者的总体死亡率为 61%,而非流感患者为 46%。RESP 评分四分位数的标准化死亡率比为 1.28(95%置信区间 0.61-2.35)。
在留尼汪,接受 VV-ECMO 治疗严重流感的患者的死亡率并不低于所有接受 VV-ECMO 治疗的患者的预期死亡率。